When and How Disease-Modifying Drugs for Multiple Sclerosis Should Be Changed in Daily Practice
Clinical and Experimental Neuroimmunology - United Kingdom
doi 10.1111/cen3.12380
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2017
Authors
Publisher
Wiley